Key facts
- This page summarizes Venrock Healthcare Capital Partners III, L.P.'s Form 4 filing for Oruka Therapeutics, Inc. (ORKA).
- 5 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2025, 18:42.
Venrock Healthcare Capital Partners III, L.P. - 10 Feb 2025 Form 4 Insider Report for Oruka Therapeutics, Inc. (ORKA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ORKA
- Reported as of
- 10 Feb 2025
- Net transaction value
- +$1,407,368
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2025, 18:42:49 UTC
- Prior SEC filing
- 11 Feb 2025
- Next SEC filing
- 14 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Venrock Healthcare Capital Partners III, L.P. filed Form 4 for Oruka Therapeutics, Inc. (ORKA) on 27 Feb 2025.
Change
- Previous filing in this sequence was filed on 11 Feb 2025.
- Current net transaction value: +$1,407,368.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORKA
transaction
Common Stock
Purchase
- Transaction value
- $6,257
- Shares
- +574
- Change %
- +0.01%
- Price
- $10.90
- Shares after
- 4,026,120
- Date
- 10 Feb 2025
- Ownership
- By Funds
- Footnotes
- F1, F2, F3
ORKA
transaction
Common Stock
Purchase
- Transaction value
- $105,043
- Shares
- +9,593
- Change %
- +0.24%
- Price
- $10.95
- Shares after
- 4,035,713
- Date
- 11 Feb 2025
- Ownership
- By Funds
- Footnotes
- F3, F4, F5
ORKA
transaction
Common Stock
Purchase
- Transaction value
- $106,396
- Shares
- +8,971
- Change %
- +0.22%
- Price
- $11.86
- Shares after
- 4,044,684
- Date
- 12 Feb 2025
- Ownership
- By Funds
- Footnotes
- F3, F6, F7
ORKA
transaction
Common Stock
Purchase
- Transaction value
- $173,868
- Shares
- +14,950
- Change %
- +0.37%
- Price
- $11.63
- Shares after
- 4,059,634
- Date
- 13 Feb 2025
- Ownership
- By Funds
- Footnotes
- F3, F8, F9
ORKA
transaction
Common Stock
Purchase
- Transaction value
- $1,015,803
- Shares
- +88,794
- Change %
- +2.2%
- Price
- $11.44
- Shares after
- 4,148,428
- Date
- 14 Feb 2025
- Ownership
- By Funds
- Footnotes
- F3, F10, F11
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 11 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.88 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F2
Consists of (i) 835,614 shares held by VHCP3; (ii) 83,701 shares held by VHCP Co-3; and (iii) 3,106,805 shares held by VHCP EG.
Footnote F3
VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
Footnote F4
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $10.86 to $11.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F5
Consists of (i) 837,271 shares held by VHCP3; (ii) 83,867 shares held by VHCP Co-3; and (iii) 3,114,575 shares held by VHCP EG.
Footnote F6
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.25 to $12.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F7
Consists of (i) 838,821 shares held by VHCP3; (ii) 84,022 shares held by VHCP Co-3; and (iii) 3,121,841 shares held by VHCP EG.
Footnote F8
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.31 to $11.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F9
Consists of (i) 841,404 shares held by VHCP3; (ii) 84,280 shares held by VHCP Co-3; and (iii) 3,133,950 shares held by VHCP EG.
Footnote F10
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $11.17 to $11.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
Footnote F11
Consists of (i) 856,747 shares held by VHCP3; (ii) 85,816 shares held by VHCP Co-3; and (iii) 3,205,865 shares held by VHCP EG.